Serum IL-6 induces HO-1 upregulation by activating the JAK2/STAT3 signaling pathway and promotes the overexpression of the antiapoptotic gene BCL-XL, thus causing lenalidomide resistance in MM cells [101]. The gene discussed is JAK2; the disease is Miyoshi myopathy.